PRINCETON, N.J., Sept. 29, 2009 (GLOBE NEWSWIRE) -- Orchid Cellmark Inc. (Nasdaq:ORCH), a leading international provider of identity DNA testing services, today announced that the company has been awarded, as sole supplier, a contract providing convicted offender DNA typing services for the State of Washington, Washington State Patrol (WSP). The award is for a two-year contract with the option for three one-year renewals.
Under the terms of the contract, Orchid expects to conduct DNA analysis for a backlog of thousands of samples submitted by WSP's CODIS Crime Laboratory (CCL) over the next six to seven months with an estimated value of approximately $875,000. Orchid had previously conducted tens of thousands of DNA tests for the State of Washington under an NIJ contract awarded in 2006. That contract ended in September of 2008.
Thomas Bologna, president and chief executive officer of Orchid Cellmark, commented, "While this award is funded by the National Institute of Justice, it is significant to note that Washington State awarded the contract to Orchid Cellmark under the new rules which allow states to have the option to choose the vendor that will process their samples." Prior to 2008, the NIJ administered all federal funded CODIS awards to the participating states, including selection of the DNA testing vendor. Starting in 2008, the states were given the option to apply for grants from the NIJ and administer the awards directly.
Mr. Bologna added, "With this award we also have a contract in place to handle future outsourcing project requirements. This is particularly important because the State of Washington is currently considering the adoption of arrestee legislation which will require the DNA sampling of persons who are arrested on qualifying charges. We expect passage of this legislation would substantially increase the number of DNA samples that would be added to the state's DNA database." Mr. Bologna concluded, "With this award, we believe Orchid is well positioned to help the State of Washington prevent backlogs in the future."
About Orchid Cellmark
Orchid Cellmark (Nasdaq:ORCH) is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. The company provides DNA family relationship testing to numerous child services organizations and individuals seeking to verify parentage. Orchid Cellmark also serves immigration and security authorities for DNA testing of individuals. In the agriculture field, the company provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these areas reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the company's reputation for exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at www.orchidcellmark.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: expectations regarding Orchid Cellmark's business operations and outlook; the company's expectation to conduct DNA analysis for a backlog of thousands of samples submitted by WSP's CODIS Crime Laboratory over the next six to seven months with an estimated value of approximately $875,000; the company's expectation that passage of arrestee legislation would substantially increase the number of DNA samples that would be added to the State of Washington's DNA database; and the company's belief that Orchid is well positioned to help the State of Washington prevent backlogs in the future. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, the risk that the amount of revenue resulting from the contract with WSP will not be significant, the risk that arrestee legislation will not substantially increase the number of DNA samples that would be added to the State of Washington's DNA database, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding and collaborations, regulatory approvals, competition, intellectual property of others, patent protection, litigation, the timing of release of federal and state funds, the timing and amount of contracts put up for bid, and Orchid Cellmark's ability to successfully offer its services directly to U.K. police forces. These risks and other additional factors affecting these forward-looking statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2008, as amended, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.
Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press release.